| abstract |
Compositions and methods for treating addiction, other diseases (including psychiatric symptoms related to or unrelated to addiction, such as anxiety, post-traumatic stress disease), and neurodegenerative diseases about. The present invention particularly relates to a pharmaceutically acceptable composition comprising methylapol as the only pharmaceutically active substance; a composition comprising methylapol and at least one additional pharmaceutically active substance; a substance which targets the HPA axis Known or modified by itself (eg, bispecific antibodies designed to penetrate the blood brain barrier, or redesigned by conjugation to substances that penetrate the blood brain barrier, for example) ) Composition; and a composition formulated so that the substance targeting the HPA axis does not significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to contain a dose that is too low to reduce plasma cortisol levels, or can be formulated to preferentially affect the skin. [Selection figure] None |